Literature DB >> 33339441

Various Aspects of a Gene Editing System-CRISPR-Cas9.

Edyta Janik1, Marcin Niemcewicz1, Michal Ceremuga2, Lukasz Krzowski3, Joanna Saluk-Bijak4, Michal Bijak1.   

Abstract

The discovery of clustered, regularly interspaced short palindromic repeats (CRISPR) and their cooperation with CRISPR-associated (Cas) genes is one of the greatest advances of the century and has marked their application as a powerful genome engineering tool. The CRISPR-Cas system was discovered as a part of the adaptive immune system in bacteria and archaea to defend from plasmids and phages. CRISPR has been found to be an advanced alternative to zinc-finger nucleases (ZFN) and transcription activator-like effector nucleases (TALEN) for gene editing and regulation, as the CRISPR-Cas9 protein remains the same for various gene targets and just a short guide RNA sequence needs to be altered to redirect the site-specific cleavage. Due to its high efficiency and precision, the Cas9 protein derived from the type II CRISPR system has been found to have applications in many fields of science. Although CRISPR-Cas9 allows easy genome editing and has a number of benefits, we should not ignore the important ethical and biosafety issues. Moreover, any tool that has great potential and offers significant capabilities carries a level of risk of being used for non-legal purposes. In this review, we present a brief history and mechanism of the CRISPR-Cas9 system. We also describe on the applications of this technology in gene regulation and genome editing; the treatment of cancer and other diseases; and limitations and concerns of the use of CRISPR-Cas9.

Entities:  

Keywords:  CRISPR–Cas9; gene editing; prime editing

Year:  2020        PMID: 33339441     DOI: 10.3390/ijms21249604

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  12 in total

Review 1.  Exploring the Involvement of the Amyloid Precursor Protein A673T Mutation against Amyloid Pathology and Alzheimer's Disease in Relation to Therapeutic Editing Tools.

Authors:  Gabriela Dumitrita Stanciu; Daniela Carmen Ababei; Razvan Nicolae Rusu; Veronica Bild; Bogdan-Ionel Tamba
Journal:  Pharmaceutics       Date:  2022-06-15       Impact factor: 6.525

Review 2.  CRISPR/Cas9 revitalizes adoptive T-cell therapy for cancer immunotherapy.

Authors:  Sasan Ghaffari; Nastaran Khalili; Nima Rezaei
Journal:  J Exp Clin Cancer Res       Date:  2021-08-26

Review 3.  Current Status of CRISPR/Cas9 Application in Clinical Cancer Research: Opportunities and Challenges.

Authors:  Saeed Rafii; Emad Tashkandi; Nedal Bukhari; Humaid O Al-Shamsi
Journal:  Cancers (Basel)       Date:  2022-02-14       Impact factor: 6.639

Review 4.  Root Breeding in the Post-Genomics Era: From Concept to Practice in Apple.

Authors:  Zhou Zhou; Lei Zhang; Jing Shu; Mengyu Wang; Han Li; Huairui Shu; Xiaoyun Wang; Qinghua Sun; Shizhong Zhang
Journal:  Plants (Basel)       Date:  2022-05-26

Review 5.  CRISPR-Cas and Its Wide-Ranging Applications: From Human Genome Editing to Environmental Implications, Technical Limitations, Hazards and Bioethical Issues.

Authors:  Roberto Piergentili; Alessandro Del Rio; Fabrizio Signore; Federica Umani Ronchi; Enrico Marinelli; Simona Zaami
Journal:  Cells       Date:  2021-04-21       Impact factor: 7.666

Review 6.  Strategies for High-Efficiency Mutation Using the CRISPR/Cas System.

Authors:  Shuying Feng; Zilong Wang; Aifang Li; Xin Xie; Junjie Liu; Shuxuan Li; Yalan Li; Baiyan Wang; Lina Hu; Lianhe Yang; Tao Guo
Journal:  Front Cell Dev Biol       Date:  2022-02-07

Review 7.  Genome Editing: A Promising Approach for Achieving Abiotic Stress Tolerance in Plants.

Authors:  Navdeep Kaur; Shubham Sharma; Mirza Hasanuzzaman; Pratap Kumar Pati
Journal:  Int J Genomics       Date:  2022-04-15       Impact factor: 2.758

Review 8.  Gene Therapy Targeting PCSK9.

Authors:  Julius L Katzmann; Arjen J Cupido; Ulrich Laufs
Journal:  Metabolites       Date:  2022-01-12

Review 9.  CRISPR Gene Editing in Lipid Disorders and Atherosclerosis: Mechanisms and Opportunities.

Authors:  Harry E Walker; Manfredi Rizzo; Zlatko Fras; Borut Jug; Maciej Banach; Peter E Penson
Journal:  Metabolites       Date:  2021-12-09

10.  Clinical applications of mesenchymal stromal cell-based therapies for pulmonary diseases: An Update and Concise Review.

Authors:  Xiaobo Chen; Feng Wang; Zhiwei Huang; Yan Wu; Jie Geng; Yuliang Wang
Journal:  Int J Med Sci       Date:  2021-06-01       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.